RATIONALE: A number of studies have associated reduced Akt1 expression with vulnerability for schizophrenia. Although mice with deletion of a single copy of the Akt1 gene (Akt1(+/-)) show reduced Akt1 expression relative to wild-type (WT) animals, the extent to which these mice show schizophrenia-like phenotypic changes and/or increased susceptibility to epigenetic or non-genetic factors related to schizophrenia is unknown. OBJECTIVES: Mutant mice were assessed on electroencephalographic/event-related potential (EEG/ERP) and behavioral (acoustic startle and pre-pulse inhibition) measures relevant to schizophrenia. Mice were also assessed following exposure to the NMDA receptor antagonist ketamine, a potent psychotomimetic drug, in order to assess the role of reduced Akt1 expression as a vulnerability factor for schizophrenia. Methods Akt1(+/-), Akt1(-/-), and WT mice received a series of paired-click, white noise stimuli, following ketamine (50 mg/kg) and saline injections. EEG was analyzed for ERPs and event-related power. Akt1(+/-) and WT mice were also assessed on PPI following ketamine (50 mg/kg) or saline injection. RESULTS: Akt1(+/-) and Akt1(-/-) mice displayed reduced amplitude of the P20 component of the ERP to the first click of a paired-click stimulus, as well as reduced S1-S2 difference for P20 and N40 components, following ketamine. Mutant mice also showed increased reduction in gamma synchrony and theta suppression following ketamine. Akt1(+/-) mice displayed reduced pre-pulse inhibition. CONCLUSIONS: Reduced genetic expression of Akt1 facilitated ketamine-induced changes of EEG and behavior in mice, suggesting that reduced Akt1 expression can serve as a vulnerability factor for schizophrenia.
RATIONALE: A number of studies have associated reduced Akt1 expression with vulnerability for schizophrenia. Although mice with deletion of a single copy of the Akt1 gene (Akt1(+/-)) show reduced Akt1 expression relative to wild-type (WT) animals, the extent to which these mice show schizophrenia-like phenotypic changes and/or increased susceptibility to epigenetic or non-genetic factors related to schizophrenia is unknown. OBJECTIVES: Mutant mice were assessed on electroencephalographic/event-related potential (EEG/ERP) and behavioral (acoustic startle and pre-pulse inhibition) measures relevant to schizophrenia. Mice were also assessed following exposure to the NMDA receptor antagonist ketamine, a potent psychotomimetic drug, in order to assess the role of reduced Akt1 expression as a vulnerability factor for schizophrenia. Methods Akt1(+/-), Akt1(-/-), and WT mice received a series of paired-click, white noise stimuli, following ketamine (50 mg/kg) and saline injections. EEG was analyzed for ERPs and event-related power. Akt1(+/-) and WT mice were also assessed on PPI following ketamine (50 mg/kg) or saline injection. RESULTS:Akt1(+/-) and Akt1(-/-) mice displayed reduced amplitude of the P20 component of the ERP to the first click of a paired-click stimulus, as well as reduced S1-S2 difference for P20 and N40 components, following ketamine. Mutant mice also showed increased reduction in gamma synchrony and theta suppression following ketamine. Akt1(+/-) mice displayed reduced pre-pulse inhibition. CONCLUSIONS: Reduced genetic expression of Akt1 facilitated ketamine-induced changes of EEG and behavior in mice, suggesting that reduced Akt1 expression can serve as a vulnerability factor for schizophrenia.
Authors: Yufei A Cao; Robert E Featherstone; Michael J Gandal; Yuling Liang; Catherine Jutzeler; John Saunders; Valerie Tatard-Leitman; Jingshan Chen; Daniel R Weinberger; Caryn Lerman; Steven J Siegel Journal: Behav Neurosci Date: 2012-02-06 Impact factor: 1.912
Authors: Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino Journal: Proc Natl Acad Sci U S A Date: 2010-12-27 Impact factor: 11.205
Authors: Darrick T Balu; Gregory C Carlson; Konrad Talbot; Hala Kazi; Tiffany E Hill-Smith; Rachel M Easton; Morris J Birnbaum; Irwin Lucki Journal: Hippocampus Date: 2010-11-03 Impact factor: 3.899
Authors: Min Wan; Rachael M Easton; Catherine E Gleason; Bobby R Monks; Kohjiro Ueki; C Ronald Kahn; Morris J Birnbaum Journal: Mol Cell Biol Date: 2011-10-28 Impact factor: 4.272
Authors: Joanna C Neill; Samuel Barnes; Samantha Cook; Ben Grayson; Nagi F Idris; Samantha L McLean; Shikha Snigdha; Lakshmi Rajagopal; Michael K Harte Journal: Pharmacol Ther Date: 2010-08-10 Impact factor: 12.310
Authors: Maciej T Lazarewicz; Richard S Ehrlichman; Christina R Maxwell; Michael J Gandal; Leif H Finkel; Steven J Siegel Journal: J Cogn Neurosci Date: 2010-07 Impact factor: 3.225
Authors: M Carlén; K Meletis; J H Siegle; J A Cardin; K Futai; D Vierling-Claassen; C Rühlmann; S R Jones; K Deisseroth; M Sheng; C I Moore; L-H Tsai Journal: Mol Psychiatry Date: 2011-04-05 Impact factor: 15.992
Authors: Russell G Port; Jeffrey I Berman; Song Liu; Robert E Featherstone; Timothy P L Roberts; Steven J Siegel Journal: Brain Connect Date: 2019-03-15
Authors: Elena Shumay; Corinde E Wiers; Ehsan Shokri-Kojori; Sung Won Kim; Colin A Hodgkinson; Hui Sun; Dardo Tomasi; Christopher T Wong; Daniel R Weinberger; Gene-Jack Wang; Joanna S Fowler; Nora D Volkow Journal: J Neurosci Date: 2017-04-17 Impact factor: 6.167
Authors: Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel Journal: Neuropsychopharmacology Date: 2014-02-14 Impact factor: 7.853